Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsIn the intricate landscape of therapeutic antibody development, understanding and quantifying a drug candidate's behavior in vivo is paramount. Pharmacokinetic (PK) and immunogenicity assays are critical pillars of this evaluation, demanding highly specific and reliable reagents. Creative Biolabs, a globally recognized leader with over two decades of expertise in antibody engineering, proudly offers a premier Idiotype Specific Single Domain Antibody (SdAb) Discovery Service. We harness the unique advantages of camelid-derived single domain antibodies to deliver unparalleled reagents for your preclinical research, empowering you to make confident, data-driven decisions.
Single domain antibodies, derived from the unique heavy-chain-only antibodies found in camelids (like llamas and alpacas), represent a paradigm shift in antibody technology. Their small size, approximately 15 kDa, and monomeric nature bestow upon them a suite of advantageous properties that overcome many limitations of conventional monoclonal antibodies.
Fig. 1 Representation of the biological material used for anti-idiotypic selection.1
At Creative Biolabs, we have integrated the latest technologies to create a powerful and efficient platform for the discovery of high-quality idiotype specific SdAbs. Our workflow is meticulously designed to deliver tailored solutions that meet your specific research objectives. We leverage a combination of state-of-the-art discovery platforms to maximize the probability of identifying the ideal anti-idiotypic SdAb for your project.
We construct highly diverse VHH libraries from immunized camelids and employ a sophisticated phage display biopanning strategy to isolate SdAbs with the desired specificity and affinity. Our proprietary panning techniques allow for the selection of SdAbs against specific conformations of your antibody drug.
Our innovative yeast display system offers a powerful alternative for screening VHH libraries. This platform allows for more quantitative selection and affinity maturation of SdAbs, ensuring the identification of candidates with optimal binding kinetics.
For projects requiring the utmost precision, we utilize cutting-edge single B cell screening platforms. This technology allows for the direct isolation and sequencing of VHH genes from individual B cells that produce the target-specific antibodies, ensuring the discovery of naturally selected, high-affinity SdAbs.
Understanding the critical role of anti-idiotypic antibodies in drug development, we offer the expertise to generate different functional types of anti-idiotypic SdAbs, each designed for a specific application in PK and ADA assays.
| Anti-Idiotypic SdAb Type | Binding Characteristics | Primary Application | Information Provided |
| Type 1: Antigen-Blocking | Binds to the paratope of the antibody drug, directly competing with the target antigen. | Free Drug PK Assays, Neutralizing Antibody (NAb) Assays | Quantifies the concentration of active, unbound drug in a sample. |
| Type 2: Antigen Non-Blocking | Binds to an idiotope outside the paratope, allowing simultaneous binding of the drug and target antigen. | Total Drug PK Assays | Measures the total concentration of the drug, including free, partially bound, and fully bound forms. |
| Type 3: Drug-target Complex-Specific | Binds only to the complex formed by the antibody drug and its target antigen. | Bound Drug PK Assays, PD Marker Analysis | Quantifies the amount of drug that has successfully engaged with its target. |
Our custom-developed anti-idiotypic SdAbs are indispensable tools for the preclinical assessment of novel antibody therapeutics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs).
Creative Biolabs is dedicated to advancing your research through the provision of exceptional and innovative solutions. Our Idiotype Specific Single Domain Antibody (SdAb) Discovery Service is a testament to this commitment, offering you the precision, reliability, and versatility required to navigate the complexities of modern biotherapeutic development.
Explore our specialized services to advance your research:
Contact us today to discuss your project with one of our experts and discover how our Idiotype Specific Single Domain Antibody Discovery Service can accelerate your path to success.
Q: What is the typical timeline for an idiotype-specific SdAb discovery project?
A: The timeline can vary depending on the complexity of the project, including the nature of the target antibody and the specific requirements for the final SdAb. However, a typical project, from immunization to the delivery of purified SdAbs, can range from 4 to 6 months. We provide a detailed project timeline with milestones at the initiation of each project.
Q: What amount of target antibody is required for immunization?
The amount of target antibody needed depends on the immunization strategy and the number of animals used. Generally, we recommend providing 5-10 mg of high-purity (>95%) therapeutic antibody to ensure a robust immune response and successful library construction. We can discuss the specific requirements for your project during our initial consultation.
Q: Can you generate anti-idiotypic SdAbs against antibody fragments like Fabs or scFvs?
Absolutely. Our platform is highly versatile and can be used to generate anti-idiotypic SdAbs against a wide range of antibody formats, including full-length IgGs, F(ab')2 fragments, Fab fragments, and single-chain variable fragments (scFvs). We will tailor the immunization and screening strategy to the specific format of your therapeutic antibody.
Q: How do you ensure the specificity of the anti-idiotypic SdAbs?
We employ a multi-step screening and characterization process to guarantee the specificity of our SdAbs. This includes negative selection against human IgG and other irrelevant antibodies to eliminate cross-reactive binders. The final candidates are rigorously tested using methods like ELISA and Surface Plasmon Resonance (SPR) to confirm their high specificity for the idiotope of your target antibody.
Q: Do you offer humanization services for the discovered SdAbs?
Yes, we provide comprehensive humanization services for camelid VHH domains. Our proprietary humanization platform effectively reduces the potential immunogenicity of the SdAbs while preserving their high affinity and specificity. This is a crucial step if the discovered SdAbs are intended for further development as therapeutic agents.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
